Incidence and risk factors of EBV reactivation after unrelated cord blood transplantation: A Eurocord and Société Française de Greffe de Moelle-Therapie Cellulaire collaborative study

Bone Marrow Transplantation

Volumn 48, Issue 2, 2013, Pages 253-256

  Dumas, P Y ^a   Ruggeri, A ^b   Robin, M ^b   Crotta, A ^b   Abraham, J ^c   Forcade, E ^a   Bay, J O ^d   Michallet, M ^e   Bertrand, Y ^e   Socie G ^b   Ionescu, I ^b   Gluckman, E ^b   Milpied, N ^a   Rocha, V ^b,f  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c LIMOGES UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^e University Hospital   (France)

^f University Hospital   (United Kingdom)

Author keywords

cord blood stem cell transplantation; EBV; post transplantation lymphoproliferative disorder

Indexed keywords

ACICLOVIR; BENZIMIDAVIR; CYCLOPHOSPHAMIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALACICLOVIR;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD ANALYSIS; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; INFECTION RISK; LEUKEMIA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; UNRELATED DONORS; VIREMIA; VIRUS LOAD; VIRUS REACTIVATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; EPSTEIN-BARR VIRUS INFECTIONS; FETAL BLOOD; HERPESVIRUS 4, HUMAN; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME; UNRELATED DONORS; VIRAL LOAD; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84873453778     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.117     Document Type: Article

References (16)

1. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481-492
2. Sundin M, Le Blanc K, Ringden O, Barkholt L, Omazic B, Lergin C et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 2006; 91: 1059-1067
3. Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM et al. Risk of lymphoproliferative disorders after bone marrow transplantation: A multiinstitutional study. Blood 1999; 94: 2208-2216
4. Landgren O, Gilbert ES, Rizzo JD, Socie G, Banks PM, Sobocinski KA et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 4992-5001
5. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: An update. Blood 2010; 115: 3861-3868
6. Barker JN, Martin PL, Coad JE, DeFor T, Trigg ME, Kurtzberg J et al. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant 2001; 7: 395-399
7. Brunstein CG, Weisdorf DJ, DeFor T, Barker JN, Tolar J, van Burik JA et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108: 2874-2880
8. Peric Z, Cahu X, Chevallier P, Brissot E, Malard F, Guillaume T et al. Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation. Bone Marrow Transplant 2012; 47: 251-257
9. Styczynski J, Reusser P, Einsele H, de la Camara R, Cordonnier C, Ward KN et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: Guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009; 43: 757-770
10. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304
11. Cohen J, Gandhi M, Naik P, Cubitt D, Rao K, Thaker U et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reducedintensity conditioning. Br J Haematol 2005; 129: 229-239
12. van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002; 99: 4364-4369
13. van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell - depleted SCT. Blood 2001; 98: 972-978
14. Chevallier P, Hebia-Fellah I, Planche L, Guillaume T, Bressolette-Bodin C, Coste-Burel M et al. Human herpes virus 6 infection is a hallmark of cord blood transplant in adults and may participate to delayed engraftment: A comparison with matched unrelated donors as stem cell source. Bone Marrow Transplant 2010; 45: 1204-1211
15. Robin M, Marque-Juillet S, Scieux C, Peffault de Latour R, Ferry C, Rocha V et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: Incidence, risk factors and outcome. Haematologica 2007; 92: 1254-1257
16. Vandenbosch K, Ovetchkine P, Champagne MA, Haddad E, Alexandrov L, Duval M. Varicella-zoster virus disease is more frequent after cord blood than after bone marrow transplantation. Biol Blood Marrow Transplant 2008; 14: 867-871